Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities

Clinically validated mRNA platform is shown to generate differentiated products across a range of indications

"The mRNA rabies vaccine program is an important validation of our discovery capability and the mRNA platform as the first of several non-COVID mRNA vaccine/therapeutics candidates," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "We continue to advance our Omicron-containing bivalent booster candidate, EVER-COVID19-M1.2, in China and other Everest territories and plan to initiate clinical trials in 2023. Building on the momentum of promising mRNA infectious disease vaccine candidates, we are well-positioned to continue innovating novel candidates using this mRNA technology platform across a wide range of disease indications."

In a head-to-head immunogenicity comparison study with a commercial inactivated rabies vaccine, mice dosed with Everest's pre-clinical rabies vaccine candidate produced higher levels of serum neutralizing antibodies than those of mice dosed with the comparator vaccine. Everest's candidate also induced a significantly higher degree of T-cell-mediated immune response than the comparator vaccine. These positive results support the clinical development of the rabies vaccine. Everest and Providence hold 50/50 global rights to develop and commercialize the new rabies vaccine.